A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors.

Trial Profile

A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Sonolisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 12 May 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 18 Nov 2010 Interim results have been presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
    • 07 Jun 2010 Enrollment is complete for the intermittent dosing group in this trial. Patients are still being recruited for the continuous dosing arm, according to an Oncothyreon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top